Table 2 ATC Categories of orphan drugs marketed in the U.S., EU, Japan and China
From: The availability and affordability of orphan drugs for rare diseases in China
ATC Category | Orphan drugs of China/U.S. | Orphan drugs of China/EU | Orphan drugs of China/Japan | Orphan drugs of China/U.S. + EU + Japanb | ||||
|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | |
A-Alimentary tract and metabolism | 6/42 | 14.3 | 1/12 | 8.3 | 6/19 | 31.6 | 10/43 | 23.3 |
B-Blood and blood forming organs | 7/40 | 17.5 | 1/3 | 33.3 | 4/11 | 36.4 | 9/31 | 29.0 |
C-Cardiovascular system | 6/9 | 66.7 | 1/5 | 20.0 | 4/7 | 57.1 | 6/13 | 46.2 |
D-Dermatologicals | 1/4 | 25.0 | 0/0 | - | 0/0 | - | 1/4 | 25 |
G-Genito-urinary system and sex hormones | 8/10 | 80.0 | 0/1 | 0 | 1/2 | 50 | 7/10 | 70 |
H- Systemic hormonal preparations, excluding sex hormones and insulins | 15/36 | 41.6 | 1/3 | 33.3 | 3/7 | 42.9 | 9/19 | 47.3 |
J- Anti-infectives for systemic use | 12/32 | 37.5 | 0/2 | 0 | 28/43 | 65.1 | 32/58 | 55.2 |
La- Antineoplastic and immunomodulating agents | 53/136 | 39.0 | 10/28 | 35.7 | 40/66 | 60.6 | 55/124 | 44.4 |
 L1 for blood cancers | 20/45 | 44.4 | 6/13 | 46.2 | 12/18 | 66.7 | 23/45 | 51.1 |
 L2 for other cancers | 23/43 | 53.5 | 4/9 | 44.4 | 6/12 | 50.0 | 16/35 | 45.7 |
M- Musculoskeletal system | 5/12 | 41.7 | 0/0 | - | 2/7 | 28.6 | 6/12 | 50.0 |
N- Nervous system | 9/31 | 29.0 | 1/6 | 16.7 | 3/11 | 27.3 | 10/33 | 30.3 |
P- Antiparasitic products, insecticides and repellents | 4/17 | 23.5 | 0/0 | - | 2/3 | 66.7 | 5/12 | 41.7 |
R- Respiratory system | 2/10 | 20 | 0/2 | 0 | 1/3 | 33.3 | 2/9 | 22.2 |
S- Sensory organs | 2/8 | 25 | 0/0 | - | 1/4 | 25 | 5/12 | 41.7 |
V- Various | 9/34 | 26.5 | 1/3 | 66.7 | 1/2 | 50 | 8/28 | 28.6 |
TOTAL | 139/421c | 33.0 | 16/65 | 24.6 | 96/185 | 52.4 | 165/408 | 40.4 |
Coefficient of Variation(C.V.) | - | 53.7 | - | 84.5 | - | 33.8 | - | 35.1 |